FlashPoint Renal Denervation Under Columbus 3D Mapping System Guidance for Treating Hypertension

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 180 participants.

Also called NCT05590871

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 180 participants (planned count) (from the registry)
Sponsor
Shanghai Hongdian Medical CO., LTD (from the registry)
Registry
  • NCT NCT05590871
Other papers using this trial's data
  • Aorticorenal Ganglion Ablation Enhances Blood Pressure Reduction After Renal Denervation Hypertension (Dallas, Tex. : 1979), 2026-07 DOI, PubMed 41954001, PMC13275075 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05590871. Randomized; single masking; primary purpose treatment. Start 2023-03-31 (actual); primary completion 2025-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
FlashPoint Renal Denervation Under Columbus 3D Mapping System Guidance for Treating Hypertension
Condition
Hypertension
Intervention (Device)
FlashPoint renal denervation system
Intervention (Other)
Sham
Lead sponsor
Shanghai Hongdian Medical CO., LTD (class: industry)

Record details

Record id
cardio:ct-nct05590871
Content hash
418eccc940b44f2768ac8bbca375b86bfbefbb26141383adbcf77c51a84bf893